Scientific Advisory Board

Oligomerix is constructing a new Scientific Advisory Board to reflect its progress towards transitioning into Clinical Phase I development in the near future. Our current Scientific Advisor is:

Steven Jacobsen, Ph.D., Senior Project Director, Neuroscience iMed, AstraZeneca Neurosciences

Dr. Jacobsen joined AstraZeneca, Neuroscience iMed as Senior Project Director in December 2012, from Proteostasis Therapeutics, a drug development startup, where he was Vice President, Head of Translational Biology Department for two years. He has extensive drug development experience in the pharmaceutical industry, with focus on neurodegeneration and the targeting of misfolded proteins, having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D, and Associate Director and Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research. Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid. In addition, he serves on the Scientific Advisory Boards of several biotechnology startup organizations, and is adjunct Associate Professor at New York University School of Medicine.